Day: December 24, 2019
NOT FOR DISSEMINATION IN THE UNITED STATESTORONTO, Dec. 24, 2019 (GLOBE NEWSWIRE) — Goliath Resources Limited (TSX-V: GOT) (OTCQB: GOTRF) (FSE: B4IE) (the “Company or “Goliath”) announces an additional non-brokered private placement of $50,000 has closed in flow-through financing for a total of $550,000 in flow-through funding raised since November 1, 2019 (see news release).This offering consisted of One Million (1,000,000) flow-through shares priced at $0.05 each and no finders’ fees were paid. It is subject to the final approval of the TSX Venture Exchange, and all shares issued pursuant to the offering will be subject to a statutory hold period of four-months plus one day from the date of closing.About GoliathGoliath Resources Limited is a project generator of precious metals projects focused...
DÉCLARATION DES TRANSACTIONS SUR ACTIONS PROPRES RÉALISÉES DU 17 DÉCEMBRE AU 19 DÉCEMBRE 2019
Written by Customer Service on . Posted in Public Companies.
CommuniquéDÉCLARATION DES TRANSACTIONS SUR ACTIONS PROPRES RÉALISÉESDU 17 DÉCEMBRE AU 19 DÉCEMBRE 2019Paris – 24 décembre 2019Dans le cadre de l’exécution de son programme de rachat d’actions annoncée par communiqué du 06 février 2019, le prestataire de service d’investissement mandaté par Klépierre a réalisé les transactions résumées dans le tableau qui suit entre le 17 décembre et le 19 décembre 2019 :
DISCLOSURE OF TRADING IN OWN SHARES FROM DECEMBER 17, 2019 TO DECEMBER 19, 2019
Written by Customer Service on . Posted in Public Companies.
RELEASEDISCLOSURE OF TRADING IN OWN SHARES FROM DECEMBER 17, 2019 TO DECEMBER 19, 2019Paris – December 24, 2019As announced in a press release dated February 06, 2019, Klépierre mandated an investment services provider to repurchase its own shares. The following table sums up the buyback transactions carried out by said provider between December 17 and December 19, 2019:
Information regarding the voting rights and shares
Written by Customer Service on . Posted in Public Companies.
24 December 2019Information regarding the voting rights and shares(Article L.233-8-II of the French Commercial Codeand 223-16 of the General Regulations of the “AMF”)Listing location: NYSE Euronext-ParisCompartiment: Eurolist AISIN code: FR 0010242511*Number of exercisable voting rights = Number of theoretical voting rights (or total number of voting rights calculated on the basis of all shares to which voting rights are attached) – number of shares without voting rights.AttachmentPR_Information_regarding_the_voting_rights_and_number_of_shares
Information relative au nombre total de droits de vote et d’actions composant le capital social
Written by Customer Service on . Posted in Public Companies.
Le 24 décembre 2019 Information relative au nombre total de droits de vote et d’actions composant le capital social(Article L. 233-8-II du Code de commerce et 223-16 du Règlement général de l’AMF)Place de cotation : NYSE Euronext-ParisCode ISIN : ...
Santa Fe Gold Appoints Daniel E. Gorski, Geologist / Technical Advisor for Exploration, Development and Mining for Santa Fe Gold, To Its Board of Directors
Written by Customer Service on . Posted in Public Companies.
ALBUQUERQUE, N.M., Dec. 24, 2019 (GLOBE NEWSWIRE) — Santa Fe Gold Corporation, (SFEG) OTC, a U.S. based mining company that currently ranks 9th out of the top ten US based mid-tier and junior precious metals companies (as cited by prestigious mining industry trade journal, The Northern Miner), with 148 mining claims covering 42 mine sites is pleased to announce with immediate effect, the appointment to its Board of Directors of Santa Fe Gold, its Geologist / Technical Advisor for Exploration, Development and Mining, Daniel E. Gorski.Mr. Gorski has served as geologist / technical advisor to Santa Fe Gold, since November 2018, and currently also serves as President and CEO of Texas Minerals Resources Corporation, TMRC.Daniel Gorski was appointed President and Chief Executive Officer of Texas Minerals Resources Corporation...
Philips completes cancellation of 8.54 million shares
Written by Customer Service on . Posted in Public Companies.
December 24, 2019Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it has completed the cancellation of 8,541,356 of its shares. The cancelled shares were acquired as part of Philips’ EUR 1.5 billion share repurchase program that started in the first quarter of 2019. Further details on the repurchase program can be found here. Philips’ current issued share capital amounts to EUR 179,346,744.20 representing 896,733,721 common shares.For further information, please contact:Steve KlinkPhilips Global Press OfficeTel.: +31 6 10888824E-mail: steve.klink@philips.comKsenija GonciarenkoPhilips Investor RelationsTel.: +31 20 5977055E-mail: ksenija.gonciarenko@philips.comAbout Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s...
Abeona Therapeutics reçoit la désignation PRIME de l’Agence européenne des médicaments pour la thérapie génique ABO-102 pour le traitement du MPS IIIA
Written by Customer Service on . Posted in Public Companies.
NEW YORK et CLEVELAND, 24 déc. 2019 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq : ABEO), un leader pleinement intégré en thérapie génique et cellulaire, a annoncé aujourd’hui que l’Agence européenne des médicaments (EMA) a accordé la désignation de Médicament prioritaire (PRIME) au programme ABO-102 de la société, qui étudie sa thérapie génique ponctuelle à base de virus adéno-associé 9 (AAV9) pour le traitement de la maladie de Sanfilippo de type A (MPS IIIA). La désignation PRIME repose sur des données cliniques et non cliniques issues de l’étude Transpher A, un essai clinique mondial de phase 1/2 évaluant une dose unique d’ABO-102...
Abeona Therapeutics erhält PRIME-Status der Europäischen Arzneimittelagentur für ABO-102 Gentherapie bei MPS IIIA
Written by Customer Service on . Posted in Public Companies.
NEW YORK und CLEVELAND, Dec. 24, 2019 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), ein vollständig integrierter Marktführer im Bereich der Gen- und Zelltherapie, hat heute bekanntgegeben, dass die Europäische Arzneimittelagentur (EMA) dem ABO-102-Programm des Unternehmens, im Rahmen dessen die Adeno-assoziierte Virus 9(AAV9)-Gentherapie bei Sanfilippo-Syndrom Typ A (MPS IIIA) untersucht wird, den PRIME-Status für unentbehrliche Medikamente verliehen hat. DerPRIME-Status basiert auf nichtklinischen Daten und klinischen Daten aus der Transpher A-Studie, einer weltweit durchgeführten klinischen Studie der Phase I/II, in der eine Einzeldosis von ABO-102 zur Behandlung von Kindern mit MPS IIIA untersucht wird.„Der PRIME-Status der EMA für das ABO-102-Programm erkennt die dringende Notwendigkeit...
Veritas Farms CEO Alexander Salgado to Appear on Yahoo Finance This Morning, Tuesday, December 24, 2019
Written by Customer Service on . Posted in Public Companies.
Fort Lauderdale, FL, Dec. 24, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Veritas Farms, Inc. (OTCQB: VFRM) (“Veritas Farms” or the “Company”), a vertically integrated agribusiness focused on the production of full spectrum hemp oil products with naturally occurring cannabinoids, is pleased to announce that its CEO, Alexander M. Salgado, will appear this morning on Yahoo Finance’s “On The Move with Adam Shapiro and Julie Hyman,” broadcasting live from 11:00 a.m. to 1:00 p.m. ET.Alexander M. Salgado, CEO and co-founder of Veritas Farms, commented, “The opportunity to discuss Veritas Farms’ recent expansions on a globally streamed business program like Yahoo Finance will put the Veritas Farms™ brand in front of a large audience of potential new customers and investors,...